Skip to search formSkip to main contentSkip to account menu

NRP104

Known as: NRP 104, NRP-104 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant used for the treatment of attention-deficit/hyperactivity… 
Review
2014
Review
2014
BackgroundHere we review the safety and tolerability profile of lisdexamfetamine dimesylate (LDX), the first long-acting prodrug… 
2012
2012
BackgroundTo examine the efficacy of lisdexamfetamine dimesylate (LDX) in adults with attention-deficit/hyperactivity disorder… 
Review
2009
Review
2009
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the prodrug lisdexamfetamine for the treatment… 
2007
2007
Background: Lisdexamfetamine dimesylate (LDX) is a therapeutically inactive amphetamine prodrug. It was developed with the goal… 
2007
2007
The human cytochrome P450 (P450) system is implicated in many drug interactions. Lisdexamfetamine dimesylate (NRP104), the… 
2006
2006
Objective: To compare the efficacy and safety of Lisdexamfetamine dimesylate (LDX; NRP104), a prodrug of d-amphetamine, with… 
2006
2006
The human cytochrome P450 (P450) system is implicated in many drug interactions. Lisdexamfetamine dimesylate (NRP104), the…